FY26 pharmacy takeda JAN-sept
Ended Awarded Last action
- Contract number
- 15B50926F00000053
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
Federal Correctional Institution Fort Worth
Correctional Facilities, Department of Justice
- Obligated
- $204,578
Award facts
- Contract value 100% obligated
- $204,577.58 Current and potential, with all options
- Completion date
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lexington, MA 02421, USA
Award details come from SAM.gov/FPDS.
About this award
The Federal Correctional Institution Fort Worth issued a delivery order valued at $204,577.58 to Takeda Pharmaceuticals America Inc. for pharmacy services spanning January through September 2026. This firm fixed-price delivery order, awarded on February 28, 2026, operates under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) as a child contract. The ordering activity represents the civilian healthcare operations of the Bureau of Prisons, which requires specialized pharmaceutical products for inmate medical care. Takeda Pharmaceuticals America Inc., headquartered in Lexington, Massachusetts, is a subsidiary of Japan-based Takeda Pharmaceutical Company Limited and serves as an established supplier of advanced biopharmaceutical products to multiple federal healthcare agencies, particularly the Department of Veterans Affairs and Bureau of Prisons facilities.
This delivery order draws from Takeda's broader single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center, valued at $131.04 million through July 14, 2026, which covers nine specialized pharmaceutical products addressing rare diseases, hemophilia, immune disorders, and hereditary angioedema. The delivery order carried no set-aside designation, reflecting the specialized and often single-source nature of these biopharmaceutical products essential to federal correctional healthcare operations. The pharmaceutical products available under the parent BPA include CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, FIRAZYR, ADZYNMA, LIVTENCITY, and GATTEX, enabling the Bureau of Prisons to procure critical medications through pre-negotiated pricing and streamlined procurement procedures.
Quick answers
Who was awarded contract 15B50926F00000053?
15B50926F00000053 was awarded to Takeda Pharmaceuticals America, Inc. by Federal Correctional Institution Fort Worth (Correctional Facilities) on February 28, 2026.
How much is contract 15B50926F00000053 worth?
The government has obligated $204,578 on 15B50926F00000053.
Is contract 15B50926F00000053 an order under another contract?
Yes. 15B50926F00000053 is a delivery order under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 15B50926F00000053 competed?
The extent of competition for 15B50926F00000053 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award